Ganga Pharmaceuticals Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Ganga Pharmaceuticals Ltd is ₹ 12 as of 12 Feb 15:30 . The P/E Ratio of Ganga Pharmaceuticals Ltd changed from 113.9 on March 2022 to 63.6 on March 2025 . This represents a CAGR of -13.56% over 4 yearsThe P/E Ratio of Novartis India Ltd changed from 65.2 on March 2021 to 19.2 on March 2025 . This represents a CAGR of -21.69% over 5 years The Market Cap of Ganga Pharmaceuticals Ltd changed from ₹ 4.16 crore on March 2022 to ₹ 4.92 crore on March 2025 . This represents a CAGR of 4.28% over 4 yearsThe Market Cap of Novartis India Ltd changed from ₹ 1362 crore on March 2021 to ₹ 1938 crore on March 2025 . This represents a CAGR of 7.30% over 5 years The revenue of Ganga Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Novartis India Ltd for the Dec '25 is ₹ 94.65 crore as compare to the Sep '25 revenue of ₹ 99.73 crore. This represent the decline of -5.09% The ebitda of Ganga Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 31.11 crore as compare to the Sep '25 ebitda of ₹ 33.28 crore. This represent the decline of -6.52% The net profit of Ganga Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Novartis India Ltd changed from ₹ 25.74 crore to ₹ 16.09 crore over 7 quarters. This represents a CAGR of -23.55% The Dividend Payout of Ganga Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Ltd was incorporated as a Public Limited Company in Aug.'94 and promoted by Brij Mohan Sharma. he Company is engaged in the business of manufacturing & trading in Pharmaceuticals & allied products (Ayurveda). In Apr.'95, the company took over Ganga pharmaceuticals, a proprietory concern (owned by the same promoter), which was manufacturing and marketing ayurvedic products since the last two decades. The company which manufactures ayurvedic medicines, started commercial production in Apr.'95.
In Jul.'96, it came out with a public issue to part-finance the expansion programme involving setting up of a new manufacturing unit for the manufacture of ayurvedic medicines at Murbad, Maharashtra. The company which commenced exports in Jan.'96, has marketing arrangements with parties located in Saudi Arabia, Dubai, Italy, Romania and Russia to market its products in their respective regions.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Ganga Pharmaceuticals Ltd and Novartis India Ltd

Which company has a larger market capitalization, Ganga Pharmaceuticals Ltd or Novartis India Ltd?

Market cap of Ganga Pharmaceuticals Ltd is 7 Cr while Market cap of Novartis India Ltd is 2,550 Cr

What are the key factors driving the stock performance of Ganga Pharmaceuticals Ltd and Novartis India Ltd?

The stock performance of Ganga Pharmaceuticals Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ganga Pharmaceuticals Ltd and Novartis India Ltd?

As of May 4, 2026, the Ganga Pharmaceuticals Ltd stock price is INR ₹12.0. On the other hand, Novartis India Ltd stock price is INR ₹1032.9.

How do dividend payouts of Ganga Pharmaceuticals Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Ganga Pharmaceuticals Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.